<?xml version="1.0" encoding="UTF-8"?>
<p id="Par166">Classification of HIV-associated neurocognitive disorders (HAND) (Antinori et al. 
 <xref ref-type="bibr" rid="CR7">2007</xref>)
 <list list-type="bullet">
  <list-item>
   <p id="Par167">Asymptomatic neurocognitive impairment (ANI)
    <list list-type="bullet">
     <list-item>
      <p id="Par168">No evidence of pre-existing cause. Cognitive impairment must be attributable to HIV and no other etiology (e.g., dementia, delirium).</p>
     </list-item>
     <list-item>
      <p id="Par169">The cognitive impairment does not interfere with activities of daily living.</p>
     </list-item>
     <list-item>
      <p id="Par170">Involves at least two cognitive areas (memory, attention, language, processing speed, sensory perceptual, motor skills) documented by performance of &gt;1 standard deviation below the mean of standardized neuropsychological testing.</p>
     </list-item>
     <list-item>
      <p id="Par171">30% prevalence in combination antiretroviral therapies (CART)-treated HIV+ individuals.</p>
     </list-item>
    </list>
   </p>
  </list-item>
  <list-item>
   <p id="Par172">Mild neurocognitive disorder (MND)
    <list list-type="bullet">
     <list-item>
      <p id="Par173">No evidence of pre-existing cause. Cognitive impairment must be attributable to HIV and no.</p>
     </list-item>
     <list-item>
      <p id="Par174">Other etiology (e.g., dementia, delirium).</p>
     </list-item>
     <list-item>
      <p id="Par175">At least mild interference in &gt;1 activities of daily living including mental acuity, inefficiency at work, homemaking or social functioning.</p>
     </list-item>
     <list-item>
      <p id="Par176">20–30% prevalence in combination antiretroviral therapies (CART)-treated HIV+ individuals.</p>
     </list-item>
    </list>
   </p>
  </list-item>
  <list-item>
   <p id="Par177">HIV-associated dementia (HAD)
    <list list-type="bullet">
     <list-item>
      <p id="Par178">No evidence of another pre-existing cause for dementia (i.e., CNS infections, CNS neoplasm, cerebrovascular disease).</p>
     </list-item>
     <list-item>
      <p id="Par179">Marked interference in activities of daily living.</p>
     </list-item>
     <list-item>
      <p id="Par180">Marked cognitive impairment involving at least two cognitive domains by performance of &gt;2 standard deviation below the mean of standardized neuropsychological tests, especially in learning of new information, slowed information processing and defective attention or concentration.</p>
     </list-item>
     <list-item>
      <p id="Par181">2–8% prevalence in combination antiretroviral therapies (CART)-treated HIV+ individuals.</p>
     </list-item>
    </list>
   </p>
  </list-item>
 </list>
</p>
